Lumipulse® G KL-6 (Krebs von den Lungen)
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of sialylated carbohydrate antigen, KL-6 in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
You will find more resources about ILDs and the KL-6 biomarker in our dedicated microsite at www.fujirebio.com/kl-6 (opens in a new window).
Product number 233207
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Other documents
FileKL-6 Whitepaper (pdf, 378.50 kb)Extra informationGuidance document on the value of measuring KL-6 in the field of lung diseases.FileKL-6 Biomarker Information - Physician Leaflet (pdf, 3.71 mb)FileLumipulse G Lung Disease Management brochure (pdf, 151.32 kb)Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Lumipulse G SARS-CoV-2 Ag was the first high-sensitive nucleocapsid protein antigen assay launched on a fully automated chemiluminescent platform.
...
May 27, 2021
Large-scale and fully automated COVID-19 antigen testing for travelers in German airports
Since November 2020 Fujirebio Europe and CENTOGENE have partnered to leverage LUMIPULSE® G technology for large-scale COVID-19 antigen testing in...
May 11, 2021
During this webinar Dr. Francesco Bonella (MD - Center for Interstitial & Rare Lung Disease, Department of Pulmonology, Ruhrlandklinik University...
Oct 19, 2020
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
